Hyperkalemia Management in Tumor Lysis Syndrome

Clinical Presentation and Diagnosis

Hyperkalemia produces the exact symptom constellation described in patients with Tumor Lysis Syndrome (TLS), including cardiac manifestations, neuromuscular effects, and body aches, due to elevated potassium levels in patients with TLS 1
The American Society of Clinical Oncology emphasizes that this combination of palpitations and muscle aches with other symptoms in a TLS patient demands immediate assessment and treatment of hyperkalemia before it progresses to life-threatening arrhythmias or cardiac arrest 1
The European Hematology Association guidelines indicate that hypocalcemia typically causes tetany and seizures rather than the symptom pattern described here, which is more characteristic of hyperkalemia 1

TLS occurs when rapid tumor cell lysis releases massive amounts of intracellular potassium into the bloodstream, particularly relevant in the 12-72 hour window after chemotherapy initiation 2
Hyperkalemia results from the abrupt release of intracellular potassium from lysed cells, exacerbated by concurrent renal failure, which impairs the kidney's ability to excrete the excess potassium load 4
Clinical TLS, which includes significant hyperkalemia, was associated with 83% mortality versus 24% in patients without clinical TLS 7
Two of four deaths in a Burkitt's lymphoma cohort were directly attributable to hyperkalemia 5, 6

The American Society of Clinical Oncology recommends immediate ECG monitoring for cardiac arrhythmias in patients with hyperkalemia 1
For severe hyperkalemia, treatment options include rapid insulin plus glucose to shift potassium intracellularly, calcium carbonate to stabilize myocardial membranes, sodium bicarbonate to correct acidosis, and emergency hemodialysis if persistent or life-threatening 1, 4
For mild hyperkalemia, treatment options include aggressive hydration, loop diuretics, and sodium polystyrene sulfonate 1, 2